Sanofi to invest $20 billion in U.S. through 2030
On Mar. 14, 2025, Sanofi announced that it plans to invest at least $20 billion in the United…
-
-
Scientists complete largest wiring diagram and functional map of the brain to date
On Apr. 9, 2025, a team of neuro scientists scientists published findings from the Machine Intelligence from Cortical…
-
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
On Mar. 9, 2025, Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and…
-
FDA approved first treatment for Rett syndrome
On Mar. 13, 2023, the U.S. Food and Drug Administration (FDA) announced that it had approved Acadia Pharmaceuticals’…
-
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
-
Zoetis Announces Agreement to Acquire Basepaws, an Innovative Leader in Petcare Genetics
On Jun. 7, 2022, Zoetis announced an agreement to acquire Basepaws, a privately held petcare genetics company, which…
-
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
-
Tonix Pharma announced exclusive collaboration with Kansas State University to develop LNP-Free mRNA vaccines
On Jan. 4, 2022, Tonix Pharmaceuticals announced an exclusive option agreement and research collaboration with Kansas State University…
-
Tonix Pharmaceuticals announced publication of paper on antiviral SARS-CoV-2 inhibitor, TNX-3500, in JCI Insight
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of ‘Sangivamycin is highly effective against SARS-CoV-2 in vitro…
-
Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Sept. 23, 2021, Tonix Pharmaceuticals announced it had expanded its research collaboration with Columbia University. The research…
-
Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome
On Jun. 21, 2021, Tonix Pharmaceuticals announced that it planned to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets)…
-
Sanofi and GSK initiated global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
On May 27, 2021, Sanofi and GlaxoSmithKline started enrolment in their Phase 3 clinical study to assess the…
-
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
-
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
-
Tonix Pharma reported positive COVID-19 vaccine efficacy results in non-human primates vaccinated with TNX-1800
On Mar. 17, 2021, Tonix Pharma announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
-
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled…
-
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
-
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
-
COVID-19 reduced US life expectancy, especially among Black and Latino populations
On Jan. 14, 2021, researchers from the University of Southern California and Princeton reported that the COVID-19 pandemic,…
-
Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program
On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…
-
Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate
On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
-
Tonix Pharmaceuticals enrolled first participant in PRECISION Study for COVID-19 vaccines and therapeutics
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
-
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
-
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
-
Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Jul. 16, 2020, Tonix Pharmaceuticals announced it had entered into a research collaboration and option agreement with…
-
Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…
-
University of Alberta researcher to test whether COVID-19 antibodies provide long-term immunity
On Jun. 25, 2020, the University of Alberta (U of A) announced a study that will analyze thousands…
-
Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration
On Jun. 18, 2020, Tonix Pharmaceuticals announced an expansion of its strategic collaboration with Southern Research to include…
-
ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…
-
Tonix Pharma announced FUJIFILM Diosynth Biotechnologies to be Manufacturing partner for COVID-19 vaccine candidate TNX-1800
On Jun. 1, 2020, Tonix Pharmaceuticals announced an agreement whereby FUJIFILM Diosynth Biotechnologies will provide contract manufacturing and…
